Scientists Map 342 Cancer Gene Mutations to Guide Treatment

Scientists just cracked the code on why some cancer mutations are more aggressive than others, opening the door to more personalized treatments that could save lives.

Researchers at the University of Edinburgh tested all 342 possible mutations in a critical section of CTNNB1, a gene that controls cell growth. When this gene malfunctions, cells can multiply uncontrollably and form tumors.

The team used advanced genome editing to measure exactly how strongly each mutation activated cancer-promoting signals in cells. Some mutations barely increased activity, while others supercharged tumor growth by up to tenfold.

What makes this discovery especially powerful is how well it matched real-world patient data. When researchers compared their lab results with genetic information from thousands of cancer patients, the mutation scores accurately predicted how tumors behaved across different tissues.

The map revealed something surprising about location. Cancers in different parts of the body favor different mutation strengths, suggesting that where a tumor grows influences which genetic changes help it thrive.

In liver cancer specifically, the researchers found two distinct patterns. Tumors with weaker CTNNB1 mutations had more immune cells present, while those with stronger mutations kept immune defenses at bay. This discovery could help doctors predict which patients might respond best to immunotherapy.

The Ripple Effect

This mutation map gives oncologists a powerful new tool for understanding individual patients. Instead of treating all CTNNB1 mutations the same way, doctors could soon tailor treatments based on the specific strength of each mutation.

The research represents years of painstaking work by teams from the University of Edinburgh, Leiden University Medical Center, and Koç University. Published in Nature Genetics, the study received funding from the Medical Research Council and the Biotechnology and Biological Sciences Research Council.

Lead researcher Andrew Wood calls it "the first study to experimentally test every possible mutation in this critical hotspot." The comprehensive approach means scientists now have a complete reference guide rather than scattered pieces of information.

The breakthrough extends beyond just one gene. The mapping technique could be applied to other cancer genes, gradually building a library that helps doctors match the right treatment to each patient's unique tumor profile.

For the thousands of people diagnosed with cancers linked to CTNNB1 mutations each year, this research brings hope that their treatment will be guided by precise scientific understanding rather than trial and error.